Work

Investigation on key molecular targets responsible for antidiabetic properties of Symplocos cochinchinensis Lour S Moore

Year: 2013
Type: dissertation
Abstract: Diabetes mellitus is a heterogeneous metabolic disorder characterized by hyperglycemia\nwith disturbances in carbohydrate, protein and lipid metabolism resulting from defects in\ninsulin secretion, insulin action or both. Currently there are 387 million people with\ndiabetes worldwide and is expected to affect 592 million people by 2035. Insulin\nresistance in peripheral tissues and pancreatic beta cell dysfunction are the major\nchallenges in the pathophysiology of diabetes. Diabetic secondary complications (like\nliver cirrhosis, retinopathy, microvascular and macrovascular complications) arise from\npersistent hyperglycemia and dyslipidemia can be disabling or even life threatening.\nCurrent medications are effective for control and management of hyperglycemia but\nundesirable effects, inefficiency against secondary complications and high cost are still\nserious issues in the present prognosis of this disorder. Hence the search for more\neffective and safer therapeutic agents of natural origin has been found to be highly\ndemanding and attract attention in the present drug discovery research. The data\navailable from Ayurveda on various medicinal plants for treatment of diabetes can\nefficiently yield potential new lead as antidiabetic agents. For wider acceptability and\npopularity of herbal remedies available in Ayurveda scientific validation by the\nelucidation of mechanism of action is very much essential. Modern biological techniques\nare available now to elucidate the biochemical basis of the effectiveness of these\nmedicinal plants. Keeping this idea the research programme under this thesis has been\nplanned to evaluate the molecular mechanism responsible for the antidiabetic property of\nSymplocos cochinchinensis, the main ingredient of Nishakathakadi Kashayam, a wellknown\nAyurvedic antidiabetic preparation. A general introduction of diabetes, its\npathophysiology, secondary complications and current treatment options, innovative\nsolutions based on phytomedicine etc has been described in Chapter 1.\nThe effect of Symplocos cochinchinensis (SC), on various in vitro biochemical targets\nrelevant to diabetes is depicted in Chapter 2 including the preparation of plant extract.\nSince diabetes is a multifactorial disease, ethanolic extract of the bark of SC (SCE) and its\nfractions (hexane, dichloromethane, ethyl acetate and 90 % ethanol) were evaluated by in\nvitro methods against multiple targets such as control of postprandial hyperglycemia,\ninsulin resistance, oxidative stress, pancreatic beta cell proliferation, inhibition of protein\nglycation, protein tyrosine phosphatase-1B (PTP-1B) and dipeptidyl peptidase-IV (DPPxxi\nIV). Among the extracts, SCE exhibited comparatively better activity like alpha\nglucosidase inhibition, insulin dependent glucose uptake (3 fold increase) in L6\nmyotubes, pancreatic beta cell regeneration in RIN-m5F and reduced triglyceride\naccumulation in 3T3-L1 cells, protection from hyperglycemia induced generation of\nreactive oxygen species in HepG2 cells with moderate antiglycation and PTP-1B\ninhibition. Chemical characterization by HPLC revealed the superiority of SCE over other\nextracts due to presence of bioactives (beta-sitosterol, phloretin 2’glucoside, oleanolic\nacid) in addition to minerals like magnesium, calcium, potassium, sodium, zinc and\nmanganese. So SCE has been subjected to oral sucrose tolerance test (OGTT) to evaluate\nits antihyperglycemic property in mild diabetic and diabetic animal models. SCE showed\nsignificant antihyperglycemic activity in in vivo diabetic models.\nChapter 3 highlights the beneficial effects of hydroethanol extract of Symplocos\ncochinchinensis (SCE) against hyperglycemia associated secondary complications in\nstreptozotocin (60 mg/kg body weight) induced diabetic rat model. Proper sanction had\nbeen obtained for all the animal experiments from CSIR-CDRI institutional animal ethics\ncommittee. The experimental groups consist of normal control (NC), N + SCE 500 mg/kg\nbwd, diabetic control (DC), D + metformin 100 mg/kg bwd, D + SCE 250 and D + SCE\n500. SCEs and metformin were administered daily for 21 days and sacrificed on day 22.\nOral glucose tolerance test, plasma insulin, % HbA1c, urea, creatinine, aspartate\naminotransferase (AST), alanine aminotransferase (ALT), albumin, total protein etc. were\nanalysed. Aldose reductase (AR) activity in the eye lens was also checked. On day 21,\nDC rats showed significantly abnormal glucose response, HOMA-IR, % HbA1c,\ndecreased activity of antioxidant enzymes and GSH, elevated AR activity, hepatic and\nrenal oxidative stress markers compared to NC. DC rats also exhibited increased level of\nplasma urea and creatinine. Treatment with SCE protected from the deleterious alterations\nof biochemical parameters in a dose dependent manner including histopathological\nalterations in pancreas. SCE 500 exhibited significant glucose lowering effect and\ndecreased HOMA-IR, % HbA1c, lens AR activity, and hepatic, renal oxidative stress and\nfunction markers compared to DC group. Considerable amount of liver and muscle\nglycogen was replenished by SCE treatment in diabetic animals. Although metformin\nshowed better effect, the activity of SCE was very much comparable with this drug.\nxxii\nThe possible molecular mechanism behind the protective property of S. cochinchinensis\nagainst the insulin resistance in peripheral tissue as well as dyslipidemia in in vivo high\nfructose saturated fat diet model is described in Chapter 4. Initially animal were fed a\nhigh fructose saturated fat (HFS) diet for a period of 8 weeks to develop insulin resistance\nand dyslipidemia. The normal diet control (ND), ND + SCE 500 mg/kg bwd, high\nfructose saturated fat diet control (HFS), HFS + metformin 100 mg/kg bwd, HFS + SCE\n250 and HFS + SCE 500 were the experimental groups. SCEs and metformin were\nadministered daily for the next 3 weeks and sacrificed at the end of 11th week. At the end\nof week 11, HFS rats showed significantly abnormal glucose and insulin tolerance,\nHOMA-IR, % HbA1c, adiponectin, lipid profile, liver glycolytic and gluconeogenic\nenzyme activities, liver and muscle triglyceride accumulation compared to ND. HFS rats\nalso exhibited increased level of plasma inflammatory cytokines, upregulated mRNA\nlevel of gluconeogenic and lipogenic genes in liver. HFS exhibited the increased\nexpression of GLUT-2 in liver and decreased expression of GLUT-4 in muscle and\nadipose. SCE treatment also preserved the architecture of pancreas, liver, and kidney\ntissues. Treatment with SCE reversed the alterations of biochemical parameters, improved\ninsulin sensitivity by modifying gene expression in liver, muscle and adipose tissues.\nOverall results suggest that SC mediates the antidiabetic activity mainly via alpha\nglucosidase inhibition, improved insulin sensitivity, with antiglycation and antioxidant\nactivities.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2231547910
Cites: 328
Cited by: 1
Related to: 10